Cargando…

Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)

Chitosan oligosaccharides (COS) display various biological activities. In this study, we aimed to explore the preventive effects of COS on glucolipid metabolism disorder using palmitic acid (PA)-induced HepG2 cells and high-fat diet (HFD)-fed C57BL/6J mice as experimental models in vitro and in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Yibo, Zheng, Junping, Yuan, Xubing, Jiao, Siming, Feng, Cui, Du, Yuguang, Liu, Hongtao, Zheng, Lanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265870/
https://www.ncbi.nlm.nih.gov/pubmed/30463189
http://dx.doi.org/10.3390/md16110455
_version_ 1783375712562970624
author Bai, Yibo
Zheng, Junping
Yuan, Xubing
Jiao, Siming
Feng, Cui
Du, Yuguang
Liu, Hongtao
Zheng, Lanyan
author_facet Bai, Yibo
Zheng, Junping
Yuan, Xubing
Jiao, Siming
Feng, Cui
Du, Yuguang
Liu, Hongtao
Zheng, Lanyan
author_sort Bai, Yibo
collection PubMed
description Chitosan oligosaccharides (COS) display various biological activities. In this study, we aimed to explore the preventive effects of COS on glucolipid metabolism disorder using palmitic acid (PA)-induced HepG2 cells and high-fat diet (HFD)-fed C57BL/6J mice as experimental models in vitro and in vivo, respectively. The results showed that COS pretreatment for 12 h significantly ameliorated lipid accumulation in HepG2 cells exposed to PA for 24 h, accompanied by a reversing of the upregulated mRNA expression of proinflammatory cytokines (IL-6, MCP-1, TNF-α) and glucolipid metabolism-related regulators (SCD-1, ACC1, PCK1-α). In addition, COS treatment alleviated glucolipid metabolism disorder in mice fed with HFD for five months, including reduction in body weight and fasting glucose, restoration of intraperitoneal glucose tolerance, and suppression of overexpression of proinflammatory cytokines and glucolipid metabolism-related regulators. Furthermore, our study found that COS pretreatment significantly reversed the downregulation of PPARγ at transcriptional and translational levels in both PA-induced HepG2 cells and liver tissues of HFD-fed mice. In summary, the study suggests that COS can improve glucolipid metabolism disorder by suppressing inflammation and upregulating PPARγ expression. This indicates a novel application of COS in preventing and treating glucolipid metabolism-related diseases.
format Online
Article
Text
id pubmed-6265870
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62658702018-12-06 Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Bai, Yibo Zheng, Junping Yuan, Xubing Jiao, Siming Feng, Cui Du, Yuguang Liu, Hongtao Zheng, Lanyan Mar Drugs Article Chitosan oligosaccharides (COS) display various biological activities. In this study, we aimed to explore the preventive effects of COS on glucolipid metabolism disorder using palmitic acid (PA)-induced HepG2 cells and high-fat diet (HFD)-fed C57BL/6J mice as experimental models in vitro and in vivo, respectively. The results showed that COS pretreatment for 12 h significantly ameliorated lipid accumulation in HepG2 cells exposed to PA for 24 h, accompanied by a reversing of the upregulated mRNA expression of proinflammatory cytokines (IL-6, MCP-1, TNF-α) and glucolipid metabolism-related regulators (SCD-1, ACC1, PCK1-α). In addition, COS treatment alleviated glucolipid metabolism disorder in mice fed with HFD for five months, including reduction in body weight and fasting glucose, restoration of intraperitoneal glucose tolerance, and suppression of overexpression of proinflammatory cytokines and glucolipid metabolism-related regulators. Furthermore, our study found that COS pretreatment significantly reversed the downregulation of PPARγ at transcriptional and translational levels in both PA-induced HepG2 cells and liver tissues of HFD-fed mice. In summary, the study suggests that COS can improve glucolipid metabolism disorder by suppressing inflammation and upregulating PPARγ expression. This indicates a novel application of COS in preventing and treating glucolipid metabolism-related diseases. MDPI 2018-11-19 /pmc/articles/PMC6265870/ /pubmed/30463189 http://dx.doi.org/10.3390/md16110455 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bai, Yibo
Zheng, Junping
Yuan, Xubing
Jiao, Siming
Feng, Cui
Du, Yuguang
Liu, Hongtao
Zheng, Lanyan
Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
title Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
title_full Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
title_fullStr Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
title_full_unstemmed Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
title_short Chitosan Oligosaccharides Improve Glucolipid Metabolism Disorder in Liver by Suppression of Obesity-Related Inflammation and Restoration of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)
title_sort chitosan oligosaccharides improve glucolipid metabolism disorder in liver by suppression of obesity-related inflammation and restoration of peroxisome proliferator-activated receptor gamma (pparγ)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265870/
https://www.ncbi.nlm.nih.gov/pubmed/30463189
http://dx.doi.org/10.3390/md16110455
work_keys_str_mv AT baiyibo chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT zhengjunping chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT yuanxubing chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT jiaosiming chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT fengcui chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT duyuguang chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT liuhongtao chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg
AT zhenglanyan chitosanoligosaccharidesimproveglucolipidmetabolismdisorderinliverbysuppressionofobesityrelatedinflammationandrestorationofperoxisomeproliferatoractivatedreceptorgammapparg